ARTICLES BY KATIE ANDERSON
-
Novo's Path To The First GLP-1 Weight Loss Pill1/23/2026
The race to the finish line for the first oral GLP-1 treatment for weight loss was won on Dec. 22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.
-
Lab Oversupply Is Pushing Leasing, Rent and Relocation Down7/1/2025
The landscape of the U.S. pharmaceutical lab market is changing, according to JLL’s U.S. Life Sciences Property Report. In addition to the effort to bring pharma manufacturing back to the U.S. ahead of looming tariffs, an oversupply of space and lower tenant demand in large biopharma markets is dropping leasing rates, rent costs and lease duration, among other changes.